| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Sotevtamab | AB-sCLU mAB; 16B5; AB-16B5 | Phase 2 Clinical | National Research Council Biotechnology Research Institute | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasm Metastasis; Solid tumours | Details |